title: Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
abstract: The American College of Rheumatology/European League Against Rheumatism established definitions of remission for rheumatoid arthritis (RA) based on composite scores, including tender (TJC) and swollen joint counts (SJC), patient global visual analog scale (VAS) score, laboratory tests, and, in the Simplified Disease Activity Index (SDAI), the physician global score. Time constraints on a physician's schedule demand an easy yet accurate tool to measure disease activity. We assessed the predictive ability of the Routine Assessment of Patient Index Data 3 (RAPID3) with and without a single swollen joint versus the SDAI and/or Boolean remission criteria for functional and radiographic outcomes.
  
  
  
  Data were from the Tocilizumab Safety and the Prevention of Structural Joint Damage phase III trial in RA patients. We assessed the ability at year 1 of a RAPID3 score of ≤3 + 1 SJC, RAPID3 score of ≤3 (remission) without SJC, SDAI score of ≤3.3 (remission), and/or Boolean remission (SJC, TJC, patient global VAS, and C-reactive protein level [mg/dl] all ≤1) to predict year 2 Health Assessment Questionnaire (HAQ) disability index (DI) score of ≤0.5 (normal), no worsening of HAQ DI score from year 1, and no worsening of Genant-modified Total Sharp Score from year 1.
  
  
  
  Among 690 patients, the mean ± SD baseline Disease Activity Score in 28 joints was 6.5 ± 0.96, RAPID3 score was 14.2 ± 5.51, and the SDAI score was 41.7 ± 13.01. Achieving year 1 measures was associated with good functional and radiographic outcomes at year 2. Sensitivity, specificity, positive predictive values, and negative predictive values were 49.1%, 83.2%, 37.4%, and 88.9% (RAPID3 remission); 26.4%, 91.7%, 36.8%, and 87.1% (RAPID3 + 1 SJC); 26.7%, 90.9%, 37.3%, and 85.9% (SDAI remission); and 17.0%, 96.6%, 47.4%, and 86.4% (Boolean remission), respectively.
  
  
  
  The predictive ability of RAPID3 (with or without joint count) was similar to that of SDAI and Boolean criteria.
authors: Mercy Catholic Medical Center, Darby, Pennsylvania.
authors: Muznay N
authors: MN
authors: Khawaja
authors: Drexel University College of Medicine, Philadelphia, Pennsylvania.
authors: Martin J
authors: MJ
authors: Bergman
authors: Genentech, South San Francisco, California.
authors: Jeffrey
authors: J
authors: Yourish
authors: Genentech, South San Francisco, California.
authors: Jinglan
authors: J
authors: Pei
authors: Genentech, South San Francisco, California.
authors: William
authors: W
authors: Reiss
authors: University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada.
authors: Edward
authors: E
authors: Keystone
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy; D004311:Double-Blind Method; D005060:Europe; D005260:Female; D006801:Humans; D007596:Joints / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance / Q000379:methods*; D017410:Practice Guidelines as Topic / Q000592:standards*; D011237:Predictive Value of Tests; D011859:Radiography / Q000379:methods / Q000592:standards*; D012074:Remission Induction; D012219:Rheumatology / Q000458:organization & administration; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012955:Societies, Medical / Q000592:standards; D016896:Treatment Outcome; D014481:United States
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab